By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
AstraZeneca PLC (NYSE:AZN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 16, 2026, AstraZeneca ...
A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...
AstraZeneca PLC (NYSE:AZN) is one of Goldman Sachs top healthcare stocks. On March 9, AstraZeneca PLC (NYSE:AZN) and Daiichi ...
Hosted on MSN
AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment
WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...
AstraZeneca announced an agreement to pay up to $2.1 billion to purchase Spanish pharmaceutical Almirall’s respiratory drug portfolio. AstraZeneca will first pay $875 million for the rights to ...
AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...
AstraZeneca PLC (NASDAQ:AZN) is one of the most profitable blue chip stocks to invest in now. Guggenheim lifted the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results